Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rhythm vs Rate Control for Postoperative Atrial Fibrillation
NCT05950971Terminated
- Sponsor
- Seoul National University Hospital
- Start
- Jul 2021
- Primary completion
- Jan 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of amiodarone, diltiazem and esmolol in Atrial fibrillation (AFib) and atrial flutter (AFL) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Rate of sinus conversion at 48 hours. Started Jul 2021; status: terminated.
02
Drugs
amiodaronediltiazemesmolol
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT05950971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05950971.